Literature DB >> 8075002

Central nervous system disease in Langerhans cell histiocytosis.

N Grois1, Y Tsunematsu, A J Barkovich, B E Favara.   

Abstract

Diabetes insipidus and anterior pituitary dysfunction, are familiar central nervous system (CNS) complications of Langerhans cell histiocytosis (LCH) but the pathophysiology and biological behaviour of other forms of CNS involvement in LCH are poorly understood. In an attempt to improve our understanding of these rare complications, we studied 23 patients with LCH in whom neuroradiological abnormalities, with or without neurological dysfunction other than diabetes insipidus, developed during the course of disease. Neuroradiological abnormalities were of three basic types (a) poorly-defined changes in white matter, (b) well-defined changes in white and grey matter and (c) extra-parenchymal "tumoural" masses. There was a profusion of associated neurological signs and symptoms in most cases but some patients were asymptomatic. The neuropathological features were complex but infiltration of the CNS by histiocytes with xanthomatous change, particularly prominent in mass lesions, was common in the 13 cases in which biopsies were done. Patients with lytic lesions of the skull and diabetes insipidus are evidently most at risk of developing these rare manifestations of LCH. Therapeutic questions could not be answered from this study because no standard treatment had been given and outcome varied widely.

Entities:  

Mesh:

Year:  1994        PMID: 8075002      PMCID: PMC2149701     

Source DB:  PubMed          Journal:  Br J Cancer Suppl        ISSN: 0306-9443


  12 in total

1.  CT and MR findings in diffuse cerebral histiocytosis: case report.

Authors:  R L Ragland; D S Moss; A W Duffis; D Wolf; J R Knorr
Journal:  AJNR Am J Neuroradiol       Date:  1991 May-Jun       Impact factor: 3.825

2.  Predominantly cerebral forms of histiocytosis-X. A reappraisal of "Gagel's hypothalamic granuloma", "granuloma infiltrans of the hypothalamus" and "Ayala's disease" with a report of four cases.

Authors:  J J Kepes; M Kepes
Journal:  Acta Neuropathol       Date:  1969       Impact factor: 17.088

3.  Xanthomatosis of the central nervous system. Clinical and pathological observations of a case with a posterior fossa syndrome.

Authors:  W Beard; D B Foster; J J Kepes; R A Guillan
Journal:  Neurology       Date:  1970-04       Impact factor: 9.910

Review 4.  Natural history of histiocytosis-X.

Authors:  D H Berry; D L Becton
Journal:  Hematol Oncol Clin North Am       Date:  1987-03       Impact factor: 3.722

5.  Results of treatment of 127 patients with systemic histiocytosis.

Authors:  J S Greenberger; A C Crocker; G Vawter; N Jaffe; J R Cassady
Journal:  Medicine (Baltimore)       Date:  1981-09       Impact factor: 1.889

6.  Histiocytosis X with involvement of brain.

Authors:  J Rubé; S De la Pava; J W Pickren
Journal:  Cancer       Date:  1967-04       Impact factor: 6.860

7.  Central nervous system disease associated with Langerhans' cell histiocytosis.

Authors:  N Grois; A J Barkovich; W Rosenau; A R Ablin
Journal:  Am J Pediatr Hematol Oncol       Date:  1993-05

Review 8.  Association of Langerhans cell histiocytosis with malignant neoplasms.

Authors:  R M Egeler; J P Neglia; D M Puccetti; C A Brennan; M E Nesbit
Journal:  Cancer       Date:  1993-02-01       Impact factor: 6.860

9.  Nephrotoxicity following carboplatin use in children: is routine monitoring of renal function necessary?

Authors:  L J Brandt; V Broadbent
Journal:  Med Pediatr Oncol       Date:  1993

10.  The frequency and natural history of diabetes insipidus in children with Langerhans-cell histiocytosis.

Authors:  D B Dunger; V Broadbent; E Yeoman; J R Seckl; S L Lightman; D B Grant; J Pritchard
Journal:  N Engl J Med       Date:  1989-10-26       Impact factor: 91.245

View more
  10 in total

1.  Functional capacity and body mass index in patients with sellar masses--cross-sectional study on 403 patients diagnosed during childhood and adolescence.

Authors:  Hermann L Müller; Ursel Gebhardt; Andreas Faldum; Angela Emser; Nicole Etavard-Gorris; Reinhard Kolb; Niels Sörensen
Journal:  Childs Nerv Syst       Date:  2005-05-12       Impact factor: 1.475

Review 2.  Langerhans cell histiocytosis (histiocytosis X).

Authors:  K Y Lam
Journal:  Postgrad Med J       Date:  1997-07       Impact factor: 2.401

3.  The diagnostic value of 18F-FDG PET and MRI in paediatric histiocytosis.

Authors:  Wolfgang Peter Mueller; Henriette Ingrid Melzer; Irene Schmid; Eva Coppenrath; Peter Bartenstein; Thomas Pfluger
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-10-25       Impact factor: 9.236

4.  Expression of cellular adhesion molecules in Langerhans cell histiocytosis and normal Langerhans cells.

Authors:  J H de Graaf; R Y Tamminga; W A Kamps; W Timens
Journal:  Am J Pathol       Date:  1995-10       Impact factor: 4.307

5.  MR imaging presentation of intracranial disease associated with Langerhans cell histiocytosis.

Authors:  Daniela Prayer; Nicole Grois; Helmut Prosch; Helmut Gadner; Anthony J Barkovich
Journal:  AJNR Am J Neuroradiol       Date:  2004-05       Impact factor: 3.825

6.  CNS Langerhans cell histiocytosis: Common hematopoietic origin for LCH-associated neurodegeneration and mass lesions.

Authors:  Kenneth L McClain; Jennifer Picarsic; Rikhia Chakraborty; Daniel Zinn; Howard Lin; Harshal Abhyankar; Brooks Scull; Albert Shih; Karen Phaik Har Lim; Olive Eckstein; Joseph Lubega; Tricia L Peters; Walter Olea; Thomas Burke; Nabil Ahmed; M John Hicks; Brandon Tran; Jeremy Jones; Robert Dauser; Michael Jeng; Robert Baiocchi; Deborah Schiff; Stanton Goldman; Kenneth M Heym; Harry Wilson; Benjamin Carcamo; Ashish Kumar; Carlos Rodriguez-Galindo; Nicholas S Whipple; Patrick Campbell; Geoffrey Murdoch; Julia Kofler; Simon Heales; Marian Malone; Randy Woltjer; Joseph F Quinn; Paul Orchard; Michael C Kruer; Ronald Jaffe; Markus G Manz; Sergio A Lira; D Williams Parsons; Miriam Merad; Tsz-Kwong Man; Carl E Allen
Journal:  Cancer       Date:  2018-04-06       Impact factor: 6.860

7.  Histiocytosis X: Characteristics, behavior, and treatments as illustrated in a case series.

Authors:  Ekkehard M Kasper; David H Aguirre-Padilla; Raanan Y Alter; Matthew Anderson
Journal:  Surg Neurol Int       Date:  2011-04-28

Review 8.  Pulmonary langerhans cell histiocytosis.

Authors:  Harpreet S Suri; Eunhee S Yi; Gregorz S Nowakowski; Robert Vassallo
Journal:  Orphanet J Rare Dis       Date:  2012-03-19       Impact factor: 4.123

9.  BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups.

Authors:  Marie-Luise Berres; Karen Phaik Har Lim; Tricia Peters; Jeremy Price; Hitoshi Takizawa; Hélène Salmon; Juliana Idoyaga; Albert Ruzo; Philip J Lupo; M John Hicks; Albert Shih; Stephen J Simko; Harshal Abhyankar; Rikhia Chakraborty; Marylene Leboeuf; Monique Beltrão; Sérgio A Lira; Kenneth M Heym; Venetia Bigley; Matthew Collin; Markus G Manz; Kenneth McClain; Miriam Merad; Carl E Allen
Journal:  J Exp Med       Date:  2014-03-17       Impact factor: 14.307

10.  Langerhans cell histiocytosis in an adult with involvement of the calvarium, cerebral cortex and brainstem: discussion of pathophysiology and rationale for the use of intravenous immune globulin.

Authors:  Christopher Dardis; Thandar Aung; William Shapiro; John Fortune; Stephen Coons
Journal:  Case Rep Neurol       Date:  2015-02-23
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.